Search

Your search keyword '"Patuzzo, Roberto"' showing total 246 results
Start Over Author "Patuzzo, Roberto"
246 results on '"Patuzzo, Roberto"'

1. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

Author

Tropea, Saveria, Del Fiore, Paolo, Maurichi, Andrea, Patuzzo, Roberto, Santinami, Mario, Ribero, Simone, Quaglino, Pietro, Caliendo, Virginia, Borgognoni, Lorenzo, Sestini, Serena, Giudice, Giuseppe, Nacchiero, Eleonora, Caracò, Corrado, Cordova, Adriana, Solari, Nicola, Piazzalunga, Dario, Tauceri, Francesca, Carcoforo, Paolo, Lombardo, Maurizio, Cavallari, Sara, and Mocellin, Simone

Published
2022
Full Text
View/download PDF

2. Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)

Author

Mandalà, Mario, Galli, Francesca, Patuzzo, Roberto, Maurichi, Andrea, Mocellin, Simone, Rossi, Carlo R., Rulli, Eliana, Montesco, Maria, Quaglino, Pietro, Caliendo, Virginia, De Giorgi, Vincenzo, Merelli, Barbara, Caracò, Corrado, Piazzalunga, Dario, Labianca, Alice, Ribero, Simone, Senetta, Rebecca, Gianatti, Andrea, Valeri, Barbara, Massi, Daniela, Ascierto, Paolo A., and Santinami, Mario

Published
2020
Full Text
View/download PDF

3. Pigmented spindle-cell nevus: A melanoma simulator

Author

Maurichi, Andrea, MD, Baldi, Marzia, MD, Bartoli, Cesare, MD, Bono, Aldo, MD, Camerini, Tiziana, PhD, Moglia, Daniele, MD, Patuzzo, Roberto, MD, Pennacchioli, Elisabetta, MD, Tragni, Gabrina, MD, and Santinami, Mario, MD

Published
2004

4. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Author

Huber, Veronica, Vallacchi, Viviana, Fleming, Viktor, Hu, Xiaoying, Cova, Agata, Dugo, Matteo, Shahaj, Eriomina, Sulsenti, Roberta, Vergani, Elisabetta, Filipazzi, Paola, De Laurentiis, Angela, Lalli, Luca, Di Guardo, Lorenza, Patuzzo, Roberto, Vergani, Barbara, Casiraghi, Elena, Cossa, Mara, Gualeni, Ambra, Bollati, Valentina, Arienti, Flavio, De Braud, Filippo, Mariani, Luigi, Villa, Antonello, Altevogt, Peter, Umansky, Viktor, Rodolfo, Monica, and Rivoltini, Licia

Subjects
Cancer patients -- Care and treatment, Immunotherapy -- Usage, MicroRNA -- Research, Suppressor cells -- Research, Treatment outcome -- Analysis, Cancer treatment, Tumors, Cell death, Infection, Melanoma, Health care industry
Abstract

The accrual of myeloid-derived suppressor cells (MDSCs) represents a major obstacle to effective immunotherapy in cancer patients, but the mechanisms underlying this process in the human setting remain elusive. Here, we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and resistance to treatment with immune checkpoint inhibitors in melanoma patients. The miRs were identified by transcriptional analyses as being responsible for the conversion of monocytes into MDSCs ([CD14.sup.+][HLA-DR.sup.neg] cells) mediated by melanoma extracellular vesicles (EVs) and were shown to recreate MDSC features upon transfection. In melanoma patients, these miRs were increased in circulating [CD14.sup.+] monocytes, plasma, and tumor samples, where they correlated with the myeloid cell infiltrate. In plasma, their baseline levels clustered with the clinical efficacy of CTLA-4 or programmed cell death protein 1 (PD-1) blockade. Hence, MDSC-related miRs represent an indicator of MDSC activity in cancer patients and a potential blood marker of a poor immunotherapy outcome., IntroductionImmunotherapy with immune checkpoint inhibitors (ICIs) has achieved a remarkable improvement in overall survival (OS) in different tumor histologies, albeit the majority of patients display intrinsic resistance (1). The response [...]

Published
2018
Full Text
View/download PDF

5. Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures

Author

Maurichi, Andrea, primary, Barretta, Francesco, additional, Patuzzo, Roberto, additional, Sala, Laura, additional, Miceli, Rosalba, additional, Gallino, Gianfranco, additional, Mattavelli, Ilaria, additional, Leva, Andrea, additional, Simonotti, Nicolò, additional, Taglione, Bianca, additional, Cossa, Mara, additional, Belotti, Alessia, additional, Valeri, Barbara, additional, Cortinovis, Umberto, additional, and Santinami, Mario, additional

Published
2023
Full Text
View/download PDF

6. Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study

Author

Mattavelli, Ilaria, primary, Patuzzo, Roberto, additional, Galeone, Carlotta, additional, Pelucchi, Claudio, additional, Gallino, Gianfranco, additional, Leva, Andrea, additional, Valeri, Barbara, additional, Santinami, Mario, additional, and Maurichi, Andrea, additional

Published
2023
Full Text
View/download PDF

9. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

18. Data from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors

Author

Di Pucchio, Tiziana, primary, Pilla, Lorenzo, primary, Capone, Imerio, primary, Ferrantini, Maria, primary, Montefiore, Enrica, primary, Urbani, Francesca, primary, Patuzzo, Roberto, primary, Pennacchioli, Elisabetta, primary, Santinami, Mario, primary, Cova, Agata, primary, Sovena, Gloria, primary, Arienti, Flavio, primary, Lombardo, Claudia, primary, Lombardi, Arianna, primary, Caporaso, Patrizia, primary, D'Atri, Stefania, primary, Marchetti, Paolo, primary, Bonmassar, Enzo, primary, Parmiani, Giorgio, primary, Belardelli, Filippo, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 5 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 4 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1-10 from Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma

Author

Anichini, Andrea, primary, Molla, Alessandra, primary, Vegetti, Claudia, primary, Bersani, Ilaria, primary, Zappasodi, Roberta, primary, Arienti, Flavio, primary, Ravagnani, Fernando, primary, Maurichi, Andrea, primary, Patuzzo, Roberto, primary, Santinami, Mario, primary, Pircher, Hanspeter, primary, Di Nicola, Massimo, primary, and Mortarini, Roberta, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

31. Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study

Author

Maurichi, Andrea, primary, Barretta, Francesco, additional, Patuzzo, Roberto, additional, Miceli, Rosalba, additional, Gallino, Gianfranco, additional, Mattavelli, Ilaria, additional, Leva, Andrea, additional, Harwood, Catherine, additional, Bergamaschi, Daniele, additional, Borg, Tiffanie‐Marie, additional, Shimonovitz‐Moore, Michal, additional, Spadola, Giuseppe, additional, Tolomio, Elena, additional, Barbieri, Consuelo, additional, Queirolo, Paola, additional, Manganoni, Ausilia Maria, additional, Pellacani, Giovanni, additional, Espeli, Vittoria, additional, Mangas, Cristina, additional, Leoni‐Parvex, Sandra, additional, Cossa, Mara, additional, Belotti, Alessia, additional, Valeri, Barbara, additional, Cortinovis, Umberto, additional, and Santinami, Mario, additional

Published
2023
Full Text
View/download PDF

32. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma

Author

Campana, Luca G, Farronato, Sofia, Hodgetts, Jackie, Odili, Joy, Vecchiato, Antonella, Bracken, Alison, Baier, Susanne, Bechara, Falk G, Borgognoni, Lorenzo, Caracò, Corrado, Carvalhal, Sara, Covarelli, Piero, Clover, James, Eisendle, Klaus, Fantini, Fabrizio, Fierro, Maria Teresa, Farricha, Victor, Gregorelli, Chiara, Hafner, Jürg, Kunte, Christian, Gerlini, Gianni, Hessam, Schapoor, Mandalà, Mario, Piazzalunga, Dario, Quaglino, Pietro, Snoj, Marko, Ross, Alastair Mackenzie, Trigona, Béatrice, Moreno-Ramirez, David, Tauceri, Francesca, Peach, Howard, Rutkowski, Piotr, Muir, Tobian, de Terlizzi, Francesca, Patuzzo, Roberto, Mühlstädt, Michael, Dietrich, Karin-Almut, Mussack, Thomas, Matteucci, Paolo, Kis, Erika, Ascierto, Paolo, Sersa, Gregor, Valpione, Sara, and Stingeni, Luca

Published
2023

34. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts

Author

Stanganelli, Ignazio, Spagnolo, Francesco, Argenziano, Giuseppe, Ascierto, Paolo A, Bassetto, Franco, Bossi, Paolo, Donato, Vittorio, Massi, Daniela, Massone, Cesare, Patuzzo, Roberto, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Zalaudek, Iris, Palmieri, Giuseppe, On Behalf Of Italian Melanoma Intergroup Imi, Null, Stanganelli, Ignazio, Spagnolo, Francesco, Argenziano, Giuseppe, Ascierto, Paolo A, Bassetto, Franco, Bossi, Paolo, Donato, Vittorio, Massi, Daniela, Massone, Cesare, Patuzzo, Roberto, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Zalaudek, Iri, Palmieri, Giuseppe, On Behalf Of Italian Melanoma Intergroup Imi, Null, Stanganelli, I., Spagnolo, F., Argenziano, G., Ascierto, P. A., Bassetto, F., Bossi, P., Donato, V., Massi, D., Massone, C., Patuzzo, R., Pellacani, G., Quaglino, P., Queirolo, P., Zalaudek, I., and Palmieri, G.

Subjects
recommendation, Cancer Research, skin cancer, cutaneous squamous cell carcinoma, immune checkpoint inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immune checkpoint inhibitor, Review, Guideline, Recommendation, keratinocyte carcinomas, immune checkpoint inhibitors, Oncology, Keratinocyte carcinoma, recommendations, anti-PD-1, cemiplimab, guidelines, immunotherapy, guideline, keratinocyte carcinoma, RC254-282
Abstract

Simple Summary Cutaneous squamous cell carcinoma is one of the most common forms of cancer. Although most cases are cured with surgical excision, a few tumors are associated with a high risk of local or distant relapse; therefore, it is relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Recently, PD-1 inhibitor cemiplimab was approved by the regulatory authorities for the treatment of advanced cutaneous squamous cell carcinoma; subsequently, the anti-PD-1 agent pembrolizumab received the approval by the FDA only in the same setting. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of cutaneous squamous cell carcinoma. Abstract Cutaneous squamous cell carcinomas (CSCC) account for about 20% of all keratinocyte carcinomas, which are the most common form of cancer. Heterogeneity of treatments and low mortality are a challenge in obtaining accurate incidence data and consistent registration in cancer registries. Indeed, CSCC mostly presents as an indolent, low-risk lesion, with five-year cure rates greater than 90% after surgical excision, and only few tumors are associated with a high-risk of local or distant relapse; therefore, it is particularly relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Due to an etiopathogenesis largely relying on chronic UV radiation exposure, CSCC is among the tumors with the highest rate of somatic mutations, which are associated with increased response rates to immunotherapy. Thanks to such strong pre-clinical rationale, clinical trials led to the approval of anti-PD-1 cemiplimab by the FDA (Food and Drug Administration) and EMA (European Medicines Agency), and anti-PD-1 pembrolizumab by the FDA only. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of CSCC.

Published
2022

35. Contributors

Author

Bennassar, Antoni, primary, Borsari, Stefania, additional, Brancaccio, Gabriella, additional, Dalle, Stephane, additional, Fargnoli, Maria Concetta, additional, Fava, Paolo, additional, Ferrara, Gerardo, additional, Fierro, Maria T., additional, Gallino, Gianfrancesco, additional, Kyrgidis, Athanassios, additional, Lallas, Aimilios, additional, Longo, Caterina, additional, Malvehy, Josep, additional, Mattavelli, Ilaria, additional, Maurichi, Andrea, additional, Moscarella, Elvira, additional, Patuzzo, Roberto, additional, Pellegrini, Cristina, additional, Peris, Ketty, additional, Puig, Susana, additional, Quaglino, Pietro, additional, Santinami, Mario, additional, Thomas, Luc, additional, and Vidal-Sicart, Sergi, additional

Published
2017
Full Text
View/download PDF

36. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.

Author

Patuzzo, Roberto, Mattavelli, Ilaria, Gallino, Gianfranco, Galeone, Carlotta, Valeri, Barbara, Mocellin, Simone, Del Fiore, Paolo, Ribero, Simone, Mandalà, Mario, Tauceri, Francesca, Lombardo, Maurizio, and Maurichi, Andrea

Subjects
*CUTANEOUS malignant melanoma, *PROPORTIONAL hazards models, *PROGNOSIS
Abstract

Background: This study aimed to improve the understanding of the prognostic value of tumor mitotic rate (TMR) in cutaneous melanoma and assessed its significance as a predictor for overall, melanoma‐specific, and recurrence‐free survival. Patients and Methods: This is a retrospective multicenter Italian cohort study of 13,016 patients diagnosed with and treated for invasive primary melanoma between 2005 and 2020 with median follow‐up of 5.5 years. The survival probability was assessed by Kaplan–Meier method, hazard ratios (HRs), and corresponding 95% confidence interval (CI) of all‐cause mortality and recurrence/death by multivariable Cox proportional hazards models. Results: Higher dermal mitoses number was associated with decreased overall survival. Among patients with TMR 0/mm2, 1/mm2, 2/mm2–3/mm2, 4/mm2–10/mm2, and >10/mm2, 5‐year overall survival (OS) was 97.3%, 93.6%, 88.3%, 73.0%, and 60.9%, respectively. In multivariate analyses, compared to TMR of 0/mm2, HRs for all‐cause mortality were 1.35 (95% CI, 1.08–1.68), 1.70 (95% CI, 1.40–2.07), 2.04 (95% CI, 1.67–2.49), and 2.39 (95% CI, 1.90–3.00) for 1 mitoses/mm2, 2 mitoses/mm2–3 mitoses/mm2, 4 mitoses/mm2–10 mitoses/mm2, and >10 mitoses/mm2, respectively. A similar increase in risks was observed in melanoma‐specific survival (MSS) and recurrence‐free survival (RFS). The HRs for MSS and RFS for the highest compared to the lowest TMR category were 3.01 (95% CI, 2.20–4.11) and 2.26 (95% CI, 1.88–2.73), respectively. Sentinel lymph‐node biopsy positivity was significantly associated with TMR increase even with adjustment for several potential confounders. Conclusions: A clear association was demonstrated between an increasing TMR and decreased OS, MSS, and RFS, suggesting a reconsideration of TMR prognostic role for future inclusion in the melanoma staging system. Plain Language Summary: The 8th American Joint Committee on Cancer for melanoma staging removed tumor mitotic rate (TMR) from the staging criteria for T1 melanomas, giving way to ulceration and tumor thickness as stronger prognostic predictors.However, it is still recommended that TMR should be assessed and recorded in all primary invasive melanomas.In a large retrospective multicenter study on primary invasive melanomas, we investigated the prognostic value of TMR to assess its significance as survival predictor.Our results showed a clear association between increasing TMR and decreased patients' survival, suggesting that TMR should be considered for inclusion in the melanoma staging system. Increasing tumor mitotic rate (TMR) is clearly associated with decreased overall, melanoma‐specific, and recurrence‐free survival. Our results suggest that the prognostic role of TMR should be reconsidered, and dermal mitotic rate should be assessed and recorded for all primary melanomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.

Author

Bossi, Paolo, primary, Alberti, Andrea, additional, Bergamini, Cristiana, additional, Resteghini, Carlo, additional, Locati, Laura Deborah, additional, Alfieri, Salvatore, additional, Cavalieri, Stefano, additional, Colombo, Elena, additional, Gurizzan, Cristina, additional, Lorini, Luigi, additional, Tovazzi, Valeria, additional, Zamparini, Manuel, additional, Ravanelli, Marco, additional, Ascierto, Paolo Antonio, additional, Rampinelli, Vittorio, additional, Grammatica, Alberto, additional, Patuzzo, Roberto, additional, Maurichi, Andrea, additional, and Licitra, Lisa F., additional

Published
2022
Full Text
View/download PDF

41. The Role Of Sentinel Node Tumor Burden In Modeling The Prognosis Of Melanoma Patients With Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup Study (N=2,086)

Author

Tropea, Saveria, primary, Fiore, Paolo Del, additional, Maurichi, Andrea, additional, Patuzzo, Roberto, additional, Santinami, Mario, additional, Ribero, Simone, additional, Quaglino, Pietro, additional, Caliendo, Virginia, additional, Borgognoni, Lorenzo, additional, Sestini, Serena, additional, Giudice, Giuseppe, additional, Nacchiero, Eleonora, additional, Caracò, Corrado, additional, Cordova, Adriana, additional, Solari, Nicola, additional, Piazzalunga, Dario, additional, Tauceri, Francesca, additional, Carcoforo, Paolo, additional, Lombardo, Maurizio, additional, Cavallari, Sara, additional, and Mocellin, Simone, additional

Published
2021
Full Text
View/download PDF

42. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response

Author

Camisaschi, Chiara, Filipazzi, Paola, Tazzari, Marcella, Casati, Chiara, Beretta, Valeria, Pilla, Lorenzo, Patuzzo, Roberto, Maurichi, Andrea, Cova, Agata, Maio, Michele, Chiarion-Sileni, Vanna, Tragni, Gabrina, Santinami, Mario, Vergani, Barbara, Villa, Antonello, Berti, Emilio, Umansky, Ludmila, Beckhove, Philipp, Umansky, Viktor, Parmiani, Giorgio, Rivoltini, Licia, and Castelli, Chiara

Published
2013
Full Text
View/download PDF

43. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma

Author

Di Guardo, Lorenza, primary, Randon, Giovanni, additional, Corti, Francesca, additional, Vallacchi, Viviana, additional, Raimondi, Alessandra, additional, Fucà, Giovanni, additional, Bini, Marta, additional, Maurichi, Andrea, additional, Patuzzo, Roberto, additional, Gallino, Gianfrancesco, additional, Mattavelli, Ilaria, additional, Ruggeri, Roberta, additional, Angi, Martina, additional, Cossa, Mara, additional, Valeri, Barbara, additional, Cimminiello, Carolina, additional, Santinami, Mario, additional, Rivoltini, Licia, additional, Braud, Filippo, additional, Rodolfo, Monica, additional, and Vecchio, Michele Del, additional

Published
2021
Full Text
View/download PDF

44. Survival in Patients With Sentinel Node–Positive Melanoma With Extranodal Extension

Author

Maurichi, Andrea, primary, Barretta, Francesco, additional, Patuzzo, Roberto, additional, Miceli, Rosalba, additional, Gallino, Gianfranco, additional, Mattavelli, Ilaria, additional, Barbieri, Consuelo, additional, Leva, Andrea, additional, Angi, Martina, additional, Lanza, Francesco Baldo, additional, Spadola, Giuseppe, additional, Cossa, Mara, additional, Nesa, Francesco, additional, Cortinovis, Umberto, additional, Sala, Laura, additional, Di Guardo, Lorenza, additional, Cimminiello, Carolina, additional, Del Vecchio, Michele, additional, Valeri, Barbara, additional, and Santinami, Mario, additional

Published
2021
Full Text
View/download PDF

49. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

Author

Pilla, Lorenzo, Patuzzo, Roberto, Rivoltini, Licia, Maio, Michele, Pennacchioli, Elisabetta, Lamaj, Elda, Maurichi, Andrea, Massarut, Samuele, Marchianò, Alfonso, Santantonio, Cristina, Tosi, Diego, Arienti, Flavio, Cova, Agata, Sovena, Gloria, Piris, Adriano, Nonaka, Daisuke, Bersani, Ilaria, Florio, Annabella Di, Luigi, Mariani, Srivastava, Pramod K., Hoos, Axel, Santinami, Mario, and Parmiani, Giorgio

Published
2006
Full Text
View/download PDF

50. Cutaneous Melanoma − Surgical Treatment

Author

Santinami, Mario, primary, Patuzzo, Roberto, additional, Ruggeri, Roberta, additional, Castelli, Gianpiero, additional, Maurichi, Andrea, additional, Baffa, Giulia, additional, and Tinti, Carlotta, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results